Epigenetic editing now stands at the forefront of durable gene regulation with the launch of optimized protein regulators, as shown in a Nature Biotechnology study targeting PCSK9 in nonhuman primates. PCSK9 controls cholesterol metabolism, and its inhibition is a well-established strategy for reducing cardiovascular disease risk.
The novel EpiReg-T (TALE-based) delivered via lipid nanoparticles achieved >90% PCSK9 silencing in macaque livers with a single dose—an effect that held for nearly a year. The study’s multi-omic evaluation in monkeys, mice, and human cells confirmed minimal off-target activity.

TALE-based epigenetic regulators represent a promising advancement in cancer therapy by enabling precise, durable modulation of gene expression without altering the DNA sequence. These engineered proteins can target specific genes and induce epigenetic modifications, such as DNA methylation and histone modifications, to stably silence oncogenes or reactivate tumor suppressor genes. Unlike traditional genetic editing, epigenetic editing via TALE-based EpiRegs offers reversibility and reduced genotoxic risk, making it highly attractive for clinical applications.

The LNP approach avoids viral-vector complications, and EpiReg-T’s modular structure allows precise reprogramming to target other disease-driving genes. Molecularly, the tool introduces targeted DNA methylation and histone modifications (notably, increases in H3K9me3) to silence gene expression for lengthy periods.

This work redefines the gene therapy paradigm, focusing on adjustable modulation without permanent DNA changes. The findings establish EpiReg-T as an adaptable, safe, and potent gene-silencing system poised for translation in both cardiovascular and additional gene-regulation therapies.

Source.